Professor, Medicine, UCSF School of Medicine
Internal Medicine
Dr. Norah A. Terrault, MD
|
|
Give Review
Doctor Norah A. Terrault, MD works in the field of Internal Medicine. He received 2 awards: "CMS Meaningful Use Stage 1 Certification" and "Fellow (FACG)". Norah Terrault is a published doctor and has 98 publications published. The lastest was: 'Safety and Efficacy of Sofosbuvir-Containing Regimens in Hepatitis C Infected Patients with Impaired Renal Function.' He is registered with Medicare.
Publications
- Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B.
- Safety and Efficacy of Sofosbuvir-Containing Regimens in Hepatitis C Infected Patients with Impaired Renal Function.
- Current Management of Hepatitis C Virus: Regimens for Peri-Liver Transplant Patients.
- Diabetes and prediabetes in patients with Hepatitis B residing in North America.
- Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.
- Author Response to: Clinical assessments of health status as a potential marker to identify patients who are too sick to undergo transplantation.
- Interferon-free Therapy for Genotype 1 Hepatitis C in Liver Transplant Recipients: Real World Experience from HCV-TARGET.
- Severe Cholestatic Hepatitis C in Transplant Recipients: No Longer A Threat to Graft Survival.
- Total 25(OH) vitamin D, free 25(OH) vitamin D and markers of bone turnover in cirrhotics with and without synthetic dysfunction.
- Telaprevir- and Boceprevir-Based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.
- High Rate of Hospital Admissions Among Patients with Cirrhosis Seeking Care in US Emergency Departments.
- Hepatitis C Direct Antiviral Drugs and Hepatic Decompensation in Patients with Advanced Cirrhosis: Culprit or Innocent Bystander?
- Treatment of Hepatitis C in Liver Transplant Patients: Interferon OUT, Direct Antiviral Combos IN.
- Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C.
- Clinician assessments of health status predict mortality in patients with end-stage liver Disease awaiting liver transplantation.
- Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
- An Interferon-free Antiviral Regimen for HCV after Liver Transplantation.
- HIV and liver transplantation: Hepatitis C is the last hurdle.
- Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation.
- Sofosbuvir, Simeprevir plus Ribavirin for Treatment of HCV Recurrence in HIV-HCV Coinfected Liver Transplant Recipients.
- Advances in Therapy for HIV-HCV Coinfected Patients in the Liver Transplant Setting.
- Survival Benefit of Repeat Liver Transplantation in the United States: A Serial MELD Analysis by Hepatitis C Status and Donor Risk Index.
- Hepatitis C Genotype Influences Post-Liver Transplant Outcomes.
- CON Sofosbuvir and Ribavirin Use in Wait-Listed Patients with Hepatitis C Should be Selective.
- Management of Hepatitis C in kidney transplant patients: on the cusp of change.
- Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and HBV Genotype.
- Hepatic artery and Biliary complications in liver transplant recipients receiving pre-transplant transarterial chemoembolization.
- Commentary: treatment of hepatitis C-related Cirrhosis in the era of direct-acting anti-virals - authors' reply.
- Frailty Predicts Waitlist Mortality in Liver Transplant Candidates.
- A US Multicenter Study of Hepatitis C Treatment of Liver Transplant Recipients with Protease-Inhibitor Triple Therapy.
- Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of Cirrhosis.
- Characteristics and Management of Patients with Chronic Hepatitis B in an Integrated Care Setting.
- Hepatitis E infection in HIV-infected liver and kidney transplant candidates.
- Hepatitis C Disease severity in living versus deceased donor liver transplant recipients: An extended observation study.
- Ending Vertical Transmission of Hepatitis B: The Third Trimester Intervention.
- Peginterferon and Ribavirin for Treatment of Recurrent Hepatitis C Disease in HCV-HIV Coinfected Liver Transplant Recipients.
- A comparison of direct and calculated free 25(OH) Vitamin D levels in clinical populations.
- Monocyte activation by interferon-α is associated with failure to achieve a sustained virologic response after treatment for Hepatitis C virus infection.
- Variability in free 25(OH) vitamin D levels in clinical populations.
- Solid Organ Transplants in HIV-Infected Patients.
- Computerized assessment of competence-related abilities in living liver donors: the Adult-to-Adult Living Donor Liver Transplantation Cohort Study.
- A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of Hepatitis C after liver transplantation.
- Correspondence Reply to MS 12-2375.
- Approach to the treatment-experienced patient with Hepatitis C virus genotype 1 infection.
- Sexual transmission of Hepatitis C virus among monogamous heterosexual couples: The HCV partners study.
- Acute Hepatitis C in an HIV-Infected patient: A Case Report and Review of Literature.
- Liver transplantation in the setting of chronic HCV.
- Outcomes of liver transplant recipients with Hepatitis C and human immunodeficiency virus coinfection.
- Risk of advanced fibrosis with grafts from Hepatitis C antibody-positive donors: A multicenter cohort study.
- Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies.
- Patient, center and geographic characteristics of nationally placed livers.
- Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent Hepatitis C virus.
- Individualizing Hepatitis B infection prophylaxis in liver transplant recipients.
- Hepatitis B virus (HBV) quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy.
- Progression of biopsy-measured liver fibrosis in untreated patients with Hepatitis C infection: non-Markov multistate model analysis.
- Management of posttransplant Hepatitis C infection.
- Specific human leukocyte antigen class I and II alleles associated with Hepatitis C virus viremia.
- Understanding the natural history of chronic HBV and HCV infections.
- The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver Disease: results from population-based surveillance.
- Complementary and alternative medicine use in chronic liver Disease patients.
- Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to Hepatitis C following liver transplant.
- Trends in waiting list registration for liver transplantation for viral Hepatitis in the United States.
- Older donors: mounting risks for the Hepatitis C-infected liver transplant recipient?
- Is recurrent Hepatitis C worse with living donors?
- Benefits and risks of combination therapy for Hepatitis B.
- Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation.
- The epidemiology of newly diagnosed chronic liver Disease in gastroenterology practices in the United States: results from population-based surveillance.
- Hepatitis C therapy before and after liver transplantation.
- Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with Hepatitis C virus infection.
- Limitations of conventionally derived chronic liver Disease mortality rates: Results of a comprehensive assessment.
- Sustained and focused Hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepa...
- Influence of cannabis use on severity of hepatitis C Disease.
- Treating chronic Hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy.
- The kidney transplant recipient with Hepatitis C infection: pre- and posttransplantation treatment.
- The changing epidemiology and natural history of Hepatitis C virus infection.
- Treating Hepatitis C infection in liver transplant recipients.
- Outcome of patients with Hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation.
- Evidence-based incorporation of serum sodium concentration into MELD.
- Management of recurrent Hepatitis C in liver transplant recipients.
- Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for Hepatitis B-induced e...
- Treatment of recurrent Hepatitis C in liver transplant recipients.
- Treatment of recurrent Hepatitis C after liver transplantation.
- Sex and Hepatitis C.
- Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver Disease.
- Serum sodium predicts mortality in patients listed for liver transplantation.
- Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related Cirrhosis.
- Chronic Hepatitis B.
- Antiviral therapy in patients with chronic hepatitis B and Cirrhosis.
- Hepatitis C etiology of liver Disease is strongly associated with early acute rejection following liver transplantation.
- Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of Hepatitis C coinfection.
- New onset diabetes mellitus after liver transplantation: the critical role of Hepatitis C infection.
- Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA).
- Prophylactic and preemptive therapies for Hepatitis C virus-infected patients undergoing liver transplantation.
- Kidney and liver transplantation in HIV-infected patients: case presentations and review.
- Hepatitis B immune globulin preparations and use in liver transplantation.
- Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study.
- Should HCV-related Cirrhosis be a contraindication for retransplantation?
Procedures Preformed
- Biliary Drainage
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- ERCP (Endoscopic Retrograde Cholangiopancreatography)
- View All
Conditions Treated
- Abdominal Pain
- Anemia
- Barrett's Esophagus
- Benign Neoplasm of the Digestive System
- View All
Doctors Specialties
- Gastroenterology
- Transplant Hepatology
- Internal Medicine
Accepted Insurances
- Aetna HMO
- Basic HMO
- Vitalidad Plus California Con Aetna
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Select Plus HMO
- Select PPO
- Access Plus Savenet
- Basic Exclusive PPO for Small Business
- Enhanced Exclusive for Small Business HMO
- Local Access Plus HMO
- Brown & Toland Physicians
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Delta Health System
- First Health (Coventry Health Care) PPO
- Blue & Gold HMO
- Covered California - Bronze PPO
- Employer Group HMO
- Health Net PPO
- Individual and Family PPO
- Medicare Advantage PFFS
- WholeCare Network HMO
- Medicaid
- Medicare MCR
- Meritain Health
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACG)
Hospital
-
UCSF Medical Center -
San Francisco General Hospital and Trauma Center
Drug Facts
| NPI NUMBER | 1225086283 | |
| NPPES Provider LastName | TERRAULT | |
| NPPES Provider FirstName | NORAH | |
| NPPES Provider ZIPCode | 941432202 | |
| NPPES Provider State | CA | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 599.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225086283 |
| Last Name Of The Provider | TERRAULT |
| First Name Of The Provider | NORAH |
| View All |
Similar Doctors
|
|
Dr. Niraj L. Sehgal, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Meredith L. Holtz, MD |
|
|
Dr. Cathleen N. Cabansag, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary J. Kemeny, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Averil I. Ma, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James C. Ryan, MD |